{
  "slug": "exscientia",
  "name": "Recursion",
  "description": "Recursion is a TechBio company that leverages artificial intelligence, machine learning, robotics, and massive datasets to decode biology and accelerate the discovery and development of new medicines. Their proprietary Recursion OS platform aims to reduce the failure rate and improve the efficiency of drug discovery, focusing on areas like aggressive cancers and rare diseases.",
  "url": "https://optimly.ai/brand/exscientia",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://www.recursion.com/",
  "baiScore": 51,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Challenger",
  "archetype_status": "active",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-07-26T00:03:21.241Z",
  "verifiedVitals": {
    "website": "https://recursion.com/",
    "founded": "2013",
    "headquarters": "Salt Lake City, UT",
    "pricing_model": "Not explicitly detailed, but typical for pharma partnerships includes milestone payments, licensing fees, and royalties on successful drug development. For internal pipeline, it's market pricing of developed drugs.",
    "core_products": "AI-driven drug discovery and development platform (Recursion OS) and a pipeline of therapeutic candidates for conditions like aggressive cancers and rare diseases.",
    "key_differentiator": "A unique, integrated TechBio approach combining proprietary, large-scale biological and chemical datasets (>50 petabytes), an automated wet lab, advanced machine learning models (Recursion OS), and a purpose-built supercomputer (BioHive-2 with NVIDIA) to create a continuous feedback loop for rapid and de-risked drug discovery.",
    "target_markets": "Patients with high unmet medical needs; pharmaceutical companies seeking accelerated and more efficient drug discovery partnerships.",
    "employee_count": "Not specified in the provided text.",
    "funding_stage": "Implied late-stage private funding or public (given clinical trials and established presence of 'more than a decade ago').",
    "subcategory": "AI-driven Drug Discovery & Development"
  },
  "intentTags": {
    "problemIntents": [
      "Traditional Pharmaceutical R&D: Relies on empirical, human-intensive laboratory experiments and clinical trials, characterized by long timelines (10-15 years), high costs (billions per drug), and a hi",
      "Contract Research Organizations (CROs): Outsourcing specific drug discovery and development tasks (e.g., toxicology, clinical trials) to specialized third-party providers. While efficient for specific",
      "Maintain Status Quo: Continuing with existing drug discovery methodologies without adopting AI or advanced computational platforms, thereby accepting current industry average costs, timelines, and suc"
    ],
    "solutionIntents": [
      "Recursion Pharma AI drug discovery",
      "Recursion pipeline oncology rare disease",
      "AI drug discovery companies",
      "Recursion BioHive-2",
      "Standalone Bioinformatics Software: Using individual computational tools or databases for specific aspects like target identification, molecular docking, or protein structure prediction, without a hol"
    ],
    "evaluationIntents": [
      "Exscientia vs Recursion"
    ]
  },
  "timestamp": 1785232532300
}